medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Decreased serum levels of inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients

Jacopo Sabbatinelli[1], Angelica Giuliani[1], Giulia Matacchione[1], Silvia Latini[1], Noemi Laprovitera[2], Giovanni Pomponio[3], Alessia Ferrarini[3], Silvia Svegliati Baroni[1], Marianna Pavani[1], Marco Moretti[4], Armando Gabrielli[1,3], Antonio Domenico Procopio[1,5], Manuela Ferracin[2], Massimiliano Bonafè[2], Fabiola Olivieri[1,5]

[1] Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy

[2] Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy

[3] Clinica Medica, Department of Internal Medicine, Ospedali Riuniti, Ancona, Italy

[4] Laboratory Medicine, Ospedali Riuniti, Ancona, Italy

[5] Center of Clinical Pathology and Innovative Therapy, IRCCS INRCA, Ancona, Italy

Corresponding authors

Fabiola Olivieri, PhD
Università Politecnica delle Marche, Department of Clinical and Molecular Sciences, DISCLIMO, Via Tronto 10/A, Ancona, Italy
E-mail: f.olivieri@univpm.it – phone: +39 071 2206242 – ORCID iD: 0000-0002-9606-1144

Massimiliano Bonafè, MD, PhD
University of Bologna, Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Via San Giacomo 14, Bologna, Italy
E-mail: massimiliano.bonafe@unibo.it – phone: +39 051 6364009 – ORCID iD: 0000-0002-5218-6551

Manuela Ferracin, PhD
University of Bologna, Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Via San Giacomo 14, Bologna, Italy
E-mail: manuela.ferracin@unibo.it – phone: +39 051 2094714 – ORCID iD: 0000-0002-1595-6887

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

ABSTRACT

Background. Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems. At least in western countries, the most amount of the death toll is accounted by old people affected by age-related diseases. In this regard, we proposed that COVID-19 severity may be tightly related to inflammaging, i.e. the age-related onset of inflammation, which is responsible for age-related diseases. It has been reported that systemic hyper-inflammation may turn to be detrimental in COVID-19 patients.

Objective. Here, we exploited a recently closed clinical trial (NCT04315480) on the anti-IL-6 drug tocilizumab to assess whether microRNAs regulating inflammaging can be assessed as biomarkers of drug response and outcome.

Methods. Serum levels of miR-146a-5p, -21-5p, and -126-3p were quantified by RT-PCR and Droplet Digital PCR by two independent laboratories on 30 patients with virologically confirmed COVID-19, characterized by multifocal interstitial pneumonia confirmed by CT-scan and requiring oxygen therapy, and 29 age- and gender-matched healthy control subjects. COVID-19 patients were treated with a single-dose intravenous infusion of 8 mg/kg tocilizumab and categorized into responders and non-responders.

Results. We showed that COVID-19 patients who did not respond to tocilizumab have lower serum levels of miR-146a-5p after the treatment (p=0.007). Moreover, among non-responders, those with the lowest serum levels of miR-146a-5p experienced the most adverse outcome (p=0.008).

Conclusion. Our data show that blood-based biomarkers, such as miR-146a-5p, can provide a molecular link between inflammaging and COVID-19 clinical course, thus allowing to enlarge the drug armory against this worldwide health threat.

Keywords: microRNA; inflammaging; COVID-19; tocilizumab; interleukin-6.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION

The COVID-19 pandemic caused by the SARS-CoV-2 coronavirus is characterized by a striking age-dependent morbidity and mortality, irrespective of ethnicity [1, 2]. In Italy, about 1.1% of COVID-19 patient deaths are attributable to people younger than 50 years, while the death toll of COVID-19 is mainly accounted by people with a median age of 82 years (IQR 74-88). Notably, most of such patients (59.7%) are affected by at least three age-related diseases [3]. Nowadays, whilst the pandemic is still spreading, COVID-19 is emerging as a transmissible age-related lethal disease, at least in western countries.

A substantial proportion of hospitalized COVID-19 patients show a systemic dysregulation of pro-inflammatory cytokines, a condition known as cytokine storm [4]. Such hyper-inflammatory response in COVID-19 patients is associated with extensive lung and endothelial cell damage, microvascular dysfunction, and microangiopathy that eventually lead to lung and multiorgan failure [5]. It is therefore unsurprising that a number of clinical trials have been started to evaluate the effectiveness of anti-cytokine/cytokine receptor antibodies as a treatment for hospitalized COVID-19 patients. Tocilizumab (TCZ), the monoclonal antibody against the interleukin-6 (IL-6) receptor is one of these host-directed therapies [6-9]. Nevertheless, substantial variability in the clinical response of COVID-19 patients to TCZ treatment has been reported, probably due to the contribution of other factors, including age-related biological mechanisms, gender, genetic makeup, disease severity, timing of treatment, and immune activation [10, 11]. With regard to the latter issue, we have recently proposed that an age-dependent pro-inflammatory status, currently referred to as inflammaging, may facilitate the onset of uncontrolled COVID-19 related hyper-inflammation, particularly in aged people [12, 13]. Blood-based biomarkers, conceivably linked to the systemic inflammatory state and/or inflammaging, and able to predict the response to TCZ treatment are urgently needed in order to redirect this precious armory to those patients who are likely to benefit at its most. Under this perspective, the assessment of serum/plasma microRNAs (miRNAs) has

medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

been emerging as a reliable tool to assess pharmacological interventions in a variety of human diseases, including age-related and infectious diseases [14].

In this regard, a set of miRNAs capable of regulating inflammation (also known as inflamma-miRs) has reported to show age-dependent changes in their blood levels and to be markers of a pro-inflammatory state (i.e. inflammaging) in healthy and non-healthy individuals [15, 16]. Of particular interest is miR-146a, whose molecular machinery directly regulates the inflammaging rate in acute myeloid leukemia patients and in a murine model of leukemia [17]. Mechanistically, miR-146a targets TRAF6/IRAK1, two key components of the NF-κB pathway, in order to induce a negative feedback loop, hence its decrease is expected to unleash inflammatory cytokines, e.g. IL-6 [17]. Other inflammatory miRNAs are co-regulated in the same scenario, including miR-21-5p and miR-126-3p, which are key regulators of angiogenic processes and endothelial inflammation [18]. The aim of this report is to evaluate the levels of circulating inflamma-miRs, such as miR-146a, miR-21-5p, and miR-126-3p [16], in COVID-19 patients treated with TCZ and age-matched healthy control subjects, in order to assess whether such biomarkers of inflammaging may be of help in such a dramatic clinical setting.

MATERIALS AND METHODS

Among the 46 patients presenting with virologically confirmed COVID-19, characterized by multifocal interstitial pneumonia confirmed by CT-scan and requiring oxygen therapy, and enrolled in a Phase 2, open-label, single-arm study at Università Politecnica delle Marche, Italy (Clinicaltrials.gov, NCT04315480), sera samples of 30 patients were available for miRNA dosage. Eligible patients presented with worsening respiratory function, defined as either decline of oxygen saturation (SO_2) > 3% or a > 50% decline in PaO_2/FiO_2 (P/F) ratio in the previous 24h; need to increase FiO_2 in order to maintain a stable SO_2 or new-onset need of mechanical ventilation; increase in number or extension of areas of pulmonary consolidation. Assessment of radiological pattern and definition of the extent of lung involvement were performed and scored as previously

medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

described [19]. Patients with severe heart failure, bacterial infection, hematological neoplasm, severe neutropenia or thrombocytopenia, and serum alanine aminotransferase > 5x UNL were excluded. All enrolled subjects provided written informed consent. The study was approved by the Regional Institutional Review Board (Comitato Etico Regione Marche) and was conducted in accordance with the Declaration of Helsinki. A Simon's optimal two-stage design was adopted. TCZ was administered as a single-dose intravenous infusion of 8 mg/kg over a 90-minute time span after premedication with 40 mg methylprednisolone. Patients were classified as responders (R) if fulfilling one of the following criteria: i) improvement of oxygen saturation by more than 3% points and/or increase in P/F by 50% and/or P/F increase above 150 mmHg 72 hours after tocilizumab AND persistence of this improvement at day 7, OR ii) no evidence of worsening of respiratory function as defined above. Dead and intubated patients were classified as Non-responders (NR). Samples of serum were collected at baseline (T0) and after 72 hours (T1) from TCZ infusion. Twenty-nine age- and gender-matched healthy control subjects (CTR), without SARS-CoV-2 infection or any other acute or chronic illness, were enrolled. Mean age of CTR was 64.1±8.6 years. MiRNAs were quantified on serum by RT-PCR and Droplet Digital PCR (ddPCR) by two independent laboratories as previously described [15, 20]. To achieve normal distribution, results were expressed as $\log_2$(relative expression) and $\log_2$(copies/µl), respectively. Results were presented as Z-scores to allow proper comparison between relative and absolute quantification.

Data were tested for normality using the Shapiro-Wilk test. Student's *t* test for independent samples and two-way mixed ANOVA with Tukey post hoc tests were used to compare the levels of investigated miRNAs between COVID-19 patients and CTR and between time points in COVID-19 patients, respectively. The agreement between RT-PCR and ddPCR was assessed using Pearson's correlation and Bland-Altman analysis. Pearson's coefficient was used for the estimation of the correlations between miRNAs expression levels and clinical parameters. Exploratory factor analysis was performed as previously described [21] to identify underlying factors in the study population.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Two-tailed p value < 0.05 was considered significant. Statistical analysis was performed using SPSS version 26 (IBM, USA).

RESULTS

The final study population was composed of 29 subjects, one sample was excluded due to hemolysis. Demographic and clinical characteristics of the samples are reported in **Table 1**. None of the patients were smokers. The median time between onset of symptoms and TCZ infusion was 9 days (IQR 4-14 days). At the end of the study, 16 patients were classified as responders (R) and 13 patients as non-responders (NR). Given the age-dependent expression of the investigated miRNAs [15], analyses were conducted after controlling for age. A significant interaction between time and responder status was found for miR-146a-5p levels ($F[1,26]=6.904$, $p=0.014$, partial $\eta^2=0.210$). A significant increase in miR-146a-5p levels was observed in R patients 3 days after the administration of TCZ (Z-score difference = 1.25; $p<0.001$). No significant differences in baseline miR-146a-5p levels were found between R and NR ($p=0.392$), while post-treatment miR-146a-5p levels were higher in R vs. NR (Z-score difference = 0.98; $p=0.007$) (**Figure 1A**). Notably, droplet digital ddPCR analysis, which allows for the quantification of miRNA copies/µl of serum, confirmed RT-PCR results ($F[1,25]=5.696$, $p=0.025$, partial $\eta^2=0.186$), with a strong Pearson's correlation between techniques (Pearson's $r=0.74$, $p<0.0001$). The Bland-Altman agreement analysis revealed a small +0.32 Z-score unit bias [95% CI: -1.09 – 1.73] between ddPCR and RT-PCR, confirming a reasonable agreement between the two methods (**Figure 1B**). Absolute quantification of miR-146a-5p copies revealed a mean increase from 3.2±1.4 to 5.3±1.3 copies per µl in R patients and a mean decrease from 3.4±1.7 to 2.1±1.6 copies per µl in NR patients.

No significant interaction between the responder status and time was showed for miR-21-5p ($F[1,26]=1.089$, $p=0.306$, partial $\eta^2=0.040$). However, the main effect of time showed that circulating miR-21-5p was 0.433 SD higher at T1 compared to T0 ($F[1,26]=5.048$, $p=0.033$, partial $\eta^2=0.163$), regardless of the responder status (**Figure 1A**). The simple main effect of time was

medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

confirmed by ddPCR (p=0.007). Bland-Altman analysis revealed a strong agreement between methods (ddPCR – RT-PCR Bias= -0.12, 95% CI: -0.26 – 0.03).

TCZ treatment does not modulate angio-miR-126-3p levels (F[1,26]=0.621, p=0.438, partial η^2=0.023), and no difference was observed between R and NR, or time points.

Multiple comparisons of age-adjusted circulating inflamma-miRs showed significantly lower miR-146-5p (mean difference = -1.498, p<0.001), miR-21-5p (mean difference = -0.486, p=0.025), and miR-126-3p (mean difference = -0.972, p<0.001) levels in COVID-19 patients compared to CTR subjects (**Figure 1A**).

Notably, age-adjusted baseline levels of miR-21-5p (p=0.016), -126-3p (p=0.006), and -146a-5p (p=0.008) were significantly lower in 5 NR COVID-19 patients who died in the 1-week follow-up period compared to NR survivors (**Figure 1C**).

Partial bivariate correlations adjusted for age were computed to analyze the relations between inflamma-miRs and selected variables, including plasma IL-6, hemoglobin, neutrophil, lymphocyte and platelet count, D-dimer, and PaO2/FiO2 ratio in COVID-19 patients at both time points. The results, summarized in the correlation plot (**Figure 1D)**, show significant positive correlations between the baseline neutrophil count and the three inflamma-miRs. Moreover, negative correlations exist between post-intervention IL-6 levels and both T0 and T1 inflamma-miR levels. The circulating levels of the three miRNAs are negatively related to D-dimer level at T1.

Finally, an exploratory factor analysis (EFA) was conducted on the COVID-19 study population to identify latent variables that could be associated with clinical outcomes. The analysis returned 5 factors cumulatively explaining 84.7% of the total variance. The first factor, which included the 3 inflamma-miRs and age, explained most of the total variance (31.3%) and was the only factor significantly associated with mortality at the univariate logistic regression (p=0.043, OR 0.07 [95% CI 0.01 – 0.91]), confirming that a latent variable encompassing low levels of circulating inflamma-miRs and increasing age is associated with mortality more than IL-6. Results of the EFA are summarized in **Figure 1E** and reported in **Supplementary Table 1**.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

DISCUSSION

To our knowledge, this is the first report showing a significant association between serum miR-146a-5p levels and response to TCZ treatment in COVID-19 patients. Two independent assays, which provide relative and absolute quantification of serum miR-146a-5p, revealed a significant increase of miR-146a-5p serum levels only in patients classified as "responders" to TCZ treatment. Since miR-146a acts as a negative regulator of the NF-κB signaling [22], our data show that TCZ response reduces the expression level of pro-inflammatory genes, such as IL-6, which are under the control of the NF-κB pathway. Notably, miR-146a-5p levels are significantly reduced in the group of non-responder COVID-19 patients with the worst outcome. Even though the number of patients is low, these results suggest that low levels of circulating miR-146a-5p in COVID-19 patients may predict poor outcome among those who develop systemic hyper-inflammation. Notably, circulating miR-146a levels significantly decline with age and chronic age-related conditions, such as type 2 diabetes [15]. Current literature agrees about its pivotal role in inflammaging and age-related diseases [17]. We recently suggested that the features of the current pandemic strongly suggest a role of inflammaging in worse COVID-19 outcomes, which mainly affect old people affected by age-related diseases [12, 13]. Interestingly, a randomized controlled trial evaluating the efficacy of a triple antiviral therapy with combined interferon beta-1b, ribavirin, and lopinavir-ritonavir on COVID-19 patients showed that the interferon-induced decline in circulating IL-6 is associated with earlier viral clearance [23]. The data herein reported confirm this prediction, showing that COVID-19 clinical course may be accelerated by inflammaging, or that COVID-19 may accelerate inflammaging itself. Overall, our results represent a proof-of-principle of the feasibility of dosing selected inflamma-miRs, specifically miR-146a-5p, as biomarkers of response to anti-inflammatory therapeutic intervention in COVID-19 patients. Moreover, such markers represent themselves as putative drug targets [22].

medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Further larger, multi-center, and possibly prospective clinical trials are necessary to identify the true potential of miR-146a-5p assessment as a predictive or prognostic biomarker in tocilizumab administration to COVID-19 patients and therefore validate the clinical relevance of our preliminary observations.

Conflicts of interest statement

The authors report no conflicts of interest.

Acknowledgments

The authors want to thank Azienda Ospedaliera Universitaria "Ospedali Riuniti", Ancona, Italy for the support.

Funding

This study was supported by grants from Università Politecnica delle Marche (RSA grant to FO and ADP) and Italian Ministry of Health ("Ricerca corrente" grant to IRCCS INRCA). MF lab is supported by Italian Association for Cancer Research (AIRC) and Pallotti Fund. MB is supported by Pallotti Fund.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES

1 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020; **46:** 846-8.

2 Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? *The Lancet* 2020; **395:** 1225-8.

3 Istituto Superiore di Sanità. Characteristics of COVID-19 patients dying in Italy. 2020.

4 Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020.

5 Varga Z, Flammer AJ, Steiger P, *et al.* Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 2020; **395:** 1417-8.

6 Xu X, Han M, Li T, *et al.* Effective treatment of severe COVID-19 patients with tocilizumab. *Proc Natl Acad Sci U S A* 2020; **117:** 10970-5.

7 Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. *J Med Virol* 2020; **92:** 814-8.

8 Crisafulli S, Isgro V, La Corte L, Atzeni F, Trifiro G. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. *BioDrugs* 2020.

9 Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? *J Autoimmun* 2020; **111:** 102452.

10 Wilk AJ, Rustagi A, Zhao NQ, *et al.* A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nat Med* 2020.

11 Khiali S, Khani E, Entezari-Maleki T. A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome. *J Clin Pharmacol* 2020.

12 Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: why older men are the most susceptible to SARS-CoV-2 complicated outcomes. *Cytokine & Growth Factor Reviews* 2020.

13 Storci G, Bonifazi F, Garagnani P, Olivieri F, Bonafe M. How studies on inflamm-aging may help to understand and combat COVID-19 pandemic. *submitted* 2020.

14 Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. *Lancet Oncol* 2012; **13:** e249-58.

15 Mensà E, Giuliani A, Matacchione G, *et al.* Circulating miR-146a in healthy aging and type 2 diabetes: Age- and gender-specific trajectories. *Mechanisms of Ageing and Development* 2019; **180:** 1-10.

16 Olivieri F, Rippo MR, Procopio AD, Fazioli F. Circulating inflamma-miRs in aging and age-related diseases. *Front Genet* 2013; **4:** 121.

17 Grants JM, Wegrzyn J, Hui T, *et al.* Altered microRNA expression links IL6 and TNF-induced inflammaging with myeloid malignancy in humans and mice. *Blood* 2020; **135:** 2235-51.

18 Zhong L, Simard MJ, Huot J. Endothelial microRNAs regulating the NF-kappaB pathway and cell adhesion molecules during inflammation. *FASEB J* 2018; **32:** 4070-84.

19 Li K, Fang Y, Li W, *et al.* CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). *Eur Radiol* 2020.

20 Ferracin M, Lupini L, Salamon I, *et al.* Absolute quantification of cell-free microRNAs in cancer patients. *Oncotarget* 2015; **6:** 14545-55.

21 Spazzafumo L, Olivieri F, Abbatecola AM, *et al.* Remodelling of biological parameters during human ageing: evidence for complex regulation in longevity and in type 2 diabetes. *Age (Dordr)* 2013; **35:** 419-29.

22 Su YL, Wang X, Mann M, *et al.* Myeloid cell-targeted miR-146a mimic inhibits NF-kappaB-driven inflammation and leukemia progression in vivo. *Blood* 2020; **135:** 167-80.

23 Hung IF, Lung KC, Tso EY, *et al.* Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet* 2020; **395:** 1695-704.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

TABLE 1. Baseline clinical and demographic characteristics of 29 COVID-19 patients treated with tocilizumab (TCZ), divided into responders (R) and non-responders (NR). Data are mean (SD). P value from *t* tests for continuous variables and *z* tests for categorical variables. LMWH, low-molecular weight heparin.

Variable	**Responder (n=16)**	**Non-responder (n=13)**	**P value**
Age (years)	65.9 (10.6)	69.4 (12.8)	0.424
Gender (males, %)	11 (68.8%)	6 (46.2%)	0.219
Time between onset of symptoms and TCZ infusion (days)	9.8 (5.9)	9.6 (3.0)	0.925
Prophylactic LMWH	10 (62.5%)	6 (46.2%)	0.379
IL-6 (pg/mL)	33.1 (40.9)	146.1 (252.4)	0.088
Hemoglobin (g/dL)	12.9 (1.7)	12.6 (1.1)	0.604
Neutrophils (n/mm^3)	5031 (2580)	6382 (3708)	0.258
Lymphocytes (n/mm^3)	673 (262)	650 (227)	0.801
Platelets (n/mm^3)	200063 (83781)	217769 (76300)	0.561
D-dimer (ng/mL)	573.1 (687.4)	1109.4 (1498.4)	0.287
PaO_2/FiO_2	146.1 (75.4)	162.2 (48.5)	0.570
1-week follow-up (n, %)			
Home discharge	16 (100%)	7 (53.8%)	0.002
Intensive care	0	1 (7.7%)	0.258
Death	0	5 (38.5%)	0.006

medRxiv preprint doi: https://doi.org/10.1101/2020.07.11.20151365; this version posted July 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

FIGURE LEGEND

Figure 1. (A) Serum levels of miR-146a-5p, -21-5p, and -126-3p in 29 COVID-19 patients at baseline (T0) and after 72 hours from treatment with tocilizumab (T1), divided into responders (R) and non-responders (NR), and in 29 age-matched healthy control subjects (CTR). Data are expressed as Z-scores of $\log_2$(relative expression) and presented as mean ± SD. *, $p<0.05$; ***, $p<0.001$ for unpaired *t* test (CTR vs. COVID-19) and for simple main effects analysis (R vs. NR). **(B)** Bland-Altman plot for inter-method agreement between Droplet Digital PCR (ddPCR) and RT-PCR in the quantification of circulating miR-146a-5p. The blue line represents the mean bias between the two methods, the dashed lines indicate the limits of agreement. **(C)** Age-adjusted baseline miR-21-5p, -126-3p, and -146-5p levels in dead vs. survivor NR patients. Data are expressed as Z-scores of $\log_2$(relative expression) and presented as estimated marginal mean ± SEM. *, $p<0.05$; **, $p<0.01$ for one-way ANCOVA. **(D)** Correlation plot showing partial correlations, controlling for age, between inflamma-miR levels and selected variables at both time points. The color and the size of the circles depend on the magnitude of the correlation. Blue, positive correlation; red, negative correlation. Significant correlations are marked with * ($p<0.05$), ** ($p<0.01$), or *** ($p<0.001$). **(E)** Summary of exploratory factor analysis and subsequent logistic regressions on COVID-19 patients. Baseline variables are reported into each circle according to the factor loading. The areas of the circles are proportional to the amount of variance (reported in brackets) explained by each factor. Overlapping circles include variables loading onto two factors. The green arrow points out the significant association between factor 1 and survival, while the gray lines indicate non-significant associations.


A
miR-146a-5p
miR-21-5p
miR-126-3p
log2(relative expression) Z-score
vs. T0
CTR
T0
T1
R
NR
B
miR-146a-5p
Mean ddPCR - RT-PCR difference
Mean of ddPCR and RT-PCR
+1.96 SD
1.73
Mean
0.32
-1.96 SD
-1.09
C
Non-responders
Adjusted T0 relative expression Z-score
survival
death
miR-21-5p
miR-126-3p
miR-146a-5p
D
T0
T1
IL-6
Neutrophils
D-dimer
Partial correlation coefficient
E
Factor 1 (31.3%)
miR-146a-5p
miR-21-5p
miR-126-3p
Age
Factor 2 (16.8%)
IL-6
Neutrophils
Factor 3 (14.6%)
Hemoglobin
Factor 4 (12.7%)
Lymphocytes
Platelets
Factor 5 (9.3%)
PaO2/FiO2
D-dimer
OR:
0.07 (0.01 - 0.91)
Survival
Clinical response